Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| NYU Langone Health | OTHER |
| Olive View-UCLA Education & Research Institute | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Financial incentives for motivating changes in health behavior, particularly for smoking and other morbid habits, are increasingly being tested by health insurers, employers, and government agencies. However, in using incentive programs for smoking cessation, key unanswered structural and theoretical questions remain regarding their effectiveness, acceptability to patients, and economic sustainability. This trial aims to advance the science and implementation of financial incentives for smoking cessation interventions among high-risk, hospitalized smokers. The investigators will pursue two specific aims: 1) comparing the impact of three approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life and 2) comparing the short-term and long term return on investment of using goal directed and outcome-based financial incentives to promote smoking cessation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Goal-Directed Incentives | Other |
| |
| Outcome-Based Incentives | Other |
| |
| Enhanced Usual Care | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Smoking cessation counseling (Quitline) | Behavioral | Quitline offers community-based counseling session with a cessation counselor. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Smoking abstinence assessed by self-report and biochemically verified by salivary cotinine | Assessed by self-report questionnaire, and biochemically verified by salivary cotinine | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Use of evidence based treatment (e.g. counseling and smoking cessation medications) assessed by discharge prescriptions, Quitline records, receipts, letters and/or self-report | Assessed by discharge prescriptions, Quitline records, receipts, letters and/or self-report | 2 months |
| Quality of life as measured by PROMIS-29 Profile v2.0 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Joseph Ladapo, MD, PhD | University of California, Los Angeles | Principal Investigator |
| Scott Sherman, MD | NYU Langone Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| David Geffen School of Medicine | Los Angeles | California | 90095 | United States | ||
| NYU Langone Health |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37775282 | Derived | Wali S, Gaitonde A, Sherman S, Min N, Pesantes A, Bidgoli A, Shirley A, Tseng CH, Ladapo J. Goal-directed versus outcome-based financial incentives for smoking cessation among low-income, hospitalised patients: rationale and design of the Financial Incentives for Smoking Treatment II (FIESTA II) randomised controlled trial. BMJ Open. 2023 Sep 29;13(9):e074354. doi: 10.1136/bmjopen-2023-074354. |
Not provided
Not provided
UCLA is committed to the ideals of collaborative research and adheres to the sponsors Grant Policy on Sharing of Unique Research Resources. Requests for research resources generated as part of this project will be distributed in a timely manner.
Publication of data shall occur during or at the end of the project, consistent with normal scientific practices. Research data that documents, supports and validates research findings will be made available after the main findings from the final research data set have been accepted for publication. Data will be redacted to prevent the disclosure of personal identifiers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy) | Behavioral | Participants will be encouraged to speak to their doctors about using highly effective pharmacotherapies for smoking cessation. |
|
| Financial incentives for smoking cessation | Behavioral | Participants will receive financial incentives for bioconfirmed smoking cessation. |
|
| Financial incentives for use of evidence-based smoking cessation therapies | Behavioral | Participants will receive financial incentives for the use of evidence-based smoking cessation therapies including Quitline counseling, community-based smoking cessation programs and pharmacotherapies |
|
Assessed by phone interviews. |
| 12 months |
| Short term return on investment of using financial incentives to promote smoking cessation (Cost analysis) | Cost analysis involving hospital utilization data, electronic health records and patient-reported healthcare utilization | 12 months |
| Long term return on investment of using financial incentives to promote smoking cessation (Cost analysis) | Cost analysis involving hospital utilization data, electronic health records and patient-reported healthcare utilization | 3 years |
| New York |
| New York |
| 10016 |
| United States |
| ID | Term |
|---|---|
| D016540 | Smoking Cessation |
| D020340 | Tobacco Use Cessation |
| ID | Term |
|---|---|
| D015438 | Health Behavior |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D000095488 | Nicotine Replacement Therapy |
| ID | Term |
|---|---|
| D004358 | Drug Therapy |
| D013812 | Therapeutics |
Not provided
Not provided